Reporting Season Round Up: Leading the charge was Playside – the ASX’s local games developer
Link copied to
Today’s top stock was Playside Studios (ASX:PLY), the only ASX listed e-sports developer that’s based in Australia.
Playside is also the newest listed ASX company in this space, debuting last December at 20 cents a share.
Shares have never traded below that point and are more than triple its IPO price.
Today, Playside reported record quarterly revenues of $4.04 million – 114% up on 12 months ago and 29% from the prior quarter.
The company also completed its first ever acquisition during the quarter and signed a strategic partnership with global games publisher Team17.
Playside’s CEO Gerry Sakkas said it was positioned extremely well to achieve a strong FY22.
Clean Teq meanwhile is in the water treatment space and recently de-merged from Sunrise Energy Metals.
Its cash receipts were only $1.6 million but this was up from just $252,000 in last year’s September quarter.
Clean Teq also signed several new contracts, one was a $1.6 million contract to deliver an EVAPX system (which evaporates water from wastewater which reduces wastewater volume) to treat wastewater an recover clean water at a NSW agriculture by-product processing facility.
Another was a $3 million contract to install a HIROX (High Recovery Reverse Osmosis) plant to treat bore water used for oil recovery in the Middle East.
While the past few quarterly reporting periods have seen many ecommerce outlets lose ground, this time has been different and Harris Technology continued the trend.
Harris reported $15.1 million in sales, up 54% from the $9.8 million made in the September quarter.
The company also boasted of achieving top seller rating on Amazon Australia where it achieved 100% positive customer reviews.
MedAdvisor’s offers a “virtual pharmacist” service that allows customers to organise their medication and scripts via smartphone.
It made $15.4 million in revenue, up 36.5% from the prior corresponding period, $12.1 million of which was in the US.
The company is tipping $59-$60 million in revenue for the calendar year and says it was well positioned for the coming quarter which is traditionally the strongest of the year.
4D Medical is a medtech company specialising in lung imaging.
During the quarter it signed its first pharmaceutical-focused contract with Novartis to commercially use its XV software.
It also completed a clinical pilot with I-MED Radiology Network in Victoria.
The company spent $8.2 million of cash in the quarter, and closed out September with a $72.2 million cash balance.